|
Events Calendar
 calendar rss feed • RSS 2.0 | | | 2009-2010 LHI Lecture Series Every Wednesday, Noon - 1pm
3-100 Mayo Auditorium - campus location / room location download schedule (pdf format, requires free Acrobat Reader)
Schedule is subject to change; check back for updates! View webcasts of previous lectures
| | Oct 21-22 | 2009 LHI/SCI Symposium see Event Page for more info • REGISTER for the symposium Wednesday, October 21
Keynote Speaker: George Q. Daley, MD, PhD
"Modeling Human Disease with Pluripotent Stem Cells"
Thursday, October 22
Stephanie Dimmeler, PhD
Jonathan A. Epstein, MD
"Notch Signaling & Cardiac Development"
Peggy Goodell, PhD
"Regulation of Hematopoietic Stem Cells"
Konrad Höchedlinger, PhD
Eric N. Olson, PhD
"MicroRNA Control of Cardiovascular Disease"
Michael A. Rudnicki, PhD
"Molecular Regulation of Muscle Stem Cell Function"
Deepak Srivastava, MD
"microRNA Regulation of Cardiac Cell Fate" see Event Page for more info • REGISTER for the symposium
| Nov 11
Wednesday |  LHI Lecture
Chronic Administration of Poloxamer 188 Prevents Cardiac Injury and Ventricular Remodeling in Dystrophic Dogs
De Wayne Townsend, DVM, PhD
Assistant Professor, Department of Integrative Biology and Physiology
University of Minnesota Medical School
Abstract:
Background: Duchenne muscular dystrophy (DMD) is a fatal disease resulting from the loss of the cytoskeletal protein dystrophin and consequent damage to both skeletal and cardiac muscle cells. In the absence of dystrophin small tears in the cardiac sarcolemma arise causing loss of membrane integrity, muscle wasting, and eventual heart failure in DMD patients. There are no reports of long-term efficacious treatments for dystrophic cardiomyopathy. Hypothesis: The long term application of the chemical-based membrane sealant Poloxamer 188 (P188) will be safe and effectively slow the development of dystrophic cardiomyopathy. Methods/Results: Here we show chronic administration of P188 to dystrophin-deficient golden retriever muscular dystrophy (GRMD) dogs in vivo is both safe and effective in blocking the development of cardiac disease. Intravenous administration of 60 mg/kg/hour P188 for 8 weeks in adult GRMD dogs prevented the onset of heart disease observed in saline infused animals. Specifically, significant reductions in fibrotic lesions were observed in P188 infusion (5.8 ±0.9% of total myocardium) compared to saline infused controls (11.0±1.1%). In saline infused dogs elevations of serum cTnI and BNP were observed. These elevations were not present in P188 infused dogs, indicating a reduction in both myocardial necrosis and congestion in P188 infused dogs. Treatment with P188 also prevented left ventricular dilation that was evident in untreated GRMD control dogs (diastolic volumes: 39±4 vs. 24±3 ml for saline and P188 infused dogs respectively). Regardless of treatment, adult cardiac myocytes isolated from either P188 or saline infused GRMD dogs revealed significantly abnormal passive tension-extension properties. These functional deficits of the isolated myocyte were rapidly reversed upon addition of P188. Conclusion: Given the clinical prominence of cardiomyopathy and heart failure in DMD, there is an urgent need for effective therapies for the dystrophic heart. This study demonstrates that P188 has the promise of an immediately available therapeutic approach for mitigating the progression of cardiac disease in DMD. Noon - 1:00pm
December 2, 2009
3-100 Mayo Auditorium (campus location / room location) download flyer
(pdf format, requires free Acrobat Reader)
| Nov 18
Wednesday | LHI Lecture
New ways to make pancreatic beta cells
Jonathan MW Slack, PhD, FMedSci
Director, Stem Cell Institute
Tulloch Chair of Stem Cell Biology
University of Minnesota
» more info about Dr. Slack from the SCI web site Abstract
Islet transplantation is an effective method of cell therapy but the supply of cells is seriously inadequate. There are various novel approaches aimed at obtaining more
beta cells. One of these is the reprogramming of other cell types by overexpression
of selected developmental transcription factors. Results will be presented using hepatocytes and biliary epithelial cells as the target cell types. Noon - 1:00pm
November 18, 2009
3-100 Mayo Auditorium (campus location / room location) download flyer
(pdf format, requires free Acrobat Reader)
| Dec 2
Wednesday | LHI Lecture
Mark Sussman, PhD
Biology Professor and Chief Research Scientist
San Diego State University Heart Institute
»more info about Dr. Sussman from the SDSU website Noon - 1:00pm
December 2, 2009
3-100 Mayo Auditorium (campus location / room location)
| Dec 9
Wednesday | LHI Lecture
Elizabeth McNally, MD, PhD
Professor of Medicine and Human Genetics
Director, Institute for Cardiovascular Research
Director, Cardiovascular Genetics Clinic
University of Chicago Medical Center
» more info about Dr. McNally from the UCMC web site Noon - 1:00pm
December 9, 2009
3-100 Mayo Auditorium (campus location / room location)
| Dec 16
Wednesday | LHI Lecture
Thomas Michel, MD, PhD
Co-Director, Leder Program in Human Biology
Translational Professor of Medicine (Biochemistry)
Federman Chair in Medical Education
Dean for Education
Harvard Medical School / Brigham and Women's Hospital
» more info about Dr. Michel from the Harvard web site Noon - 1:00pm
December 16, 2009
3-100 Mayo Auditorium (campus location / room location)
| | calendar rss feed • RSS 2.0 |
|
